SCHEMBL5022980

SCHEMBL5022980

Oc1cc(-c2ccco2)nc(-c2cccnc2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.59
HSD17B10 Q99714 5/20 0.59
ALOX15 P16050 4/20 0.59
HPGD P15428 3/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
MAPT P10636 3/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
LMNA P02545 2/20 0.59
TSHR P16473 2/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
KDM4E B2RXH2 4/20 0.49
MAPK1 P28482 2/20 0.47
GLA P06280 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
BRCA1 P38398 1/20 0.47
RECQL P46063 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5017830 0.85 SMN1; SMN2 (0.55) ALDH1A1HSD17B10ALOX15HPGDMEN1
SCHEMBL5026343 0.83 ALDH1A1 (0.57) ALDH1A1HSD17B10ALOX15HPGDMEN1
SCHEMBL5016320 0.83 ALDH1A1 (0.57) ALDH1A1HSD17B10ALOX15HPGDMEN1
SCHEMBL4631807 0.83 KDM4E (0.57) ALDH1A1HSD17B10ALOX15HPGDMAPT
SCHEMBL30060579 0.83 KDM4E (0.57) ALDH1A1HSD17B10ALOX15HPGDMAPT
SCHEMBL10168729 0.76 CYP19A1 (0.62) ALDH1A1MEN1KMT2ASMN1; SMN2TSHR
SCHEMBL5017712 0.75 ADORA3 (0.73) NPC1RAB9AKDM4EMCL1ADORA3
SCHEMBL29941611 0.75 ALDH1A1 (0.67) ALDH1A1HSD17B10ALOX15HPGDMEN1
SCHEMBL2099095 0.75 ALDH1A1 (0.67) ALDH1A1HSD17B10ALOX15HPGDMEN1
SCHEMBL5016195 0.74 KDM4E (0.66) ALDH1A1HSD17B10ALOX15HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
CN-1953975-A 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists ALMIRALL PRODESFARMA AG (CH) 2007-04-25 CN disclosed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 ALDH1A1 408/4885HSD17B10 4085/4885ALOX15 1549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.